The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis  by Bin, Lianghua et al.
The short splice form of Casper/c-FLIP is a major cellular inhibitor of
TRAIL-induced apoptosis
Lianghua Bina, Xiaoyan Lia, Liang-Guo Xua, Hong-Bing Shua;b;*
aDepartment of Immunology and CU Cancer Center, National Jewish Medical and Research Center, University of Colorado Health Sciences Center,
1400 Jackson Street, K516c, Denver, CO 80206, USA
bDepartment of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871, PR China
Received 24 September 2001; revised 20 November 2001; accepted 20 November 2001
First published online 4 December 2001
Edited by Giulio Superti-Furga
Abstract TRAIL (tumor necrosis factor-related apoptosis-
inducing ligand) is a member of the tumor necrosis factor family
that selectively induces apoptosis of cancer cells. However, some
cancer cells or subpopulations within cancer cell lines are
resistant to TRAIL-induced apoptosis. We developed a retroviral
cDNA library-based functional cloning approach to unambigu-
ously identify putative inhibitory genes of TRAIL-induced
apoptosis. This effort identified the short splice form of
Casper/c-FLIP, Casper-S/c-FLIPs, as a major cellular protein
that confers resistance to TRAIL-induced apoptosis. Further-
more, we found that Casper deficient embryonic fibroblasts
(EFs) were highly sensitive while their wild-type counterparts
were completely resistant to TRAIL-induced apoptosis. Retro-
viral-mediated transduction of Casper-S/c-FLIPs into Casper
(3/3) EFs restored resistance to TRAIL. These data suggest
that Casper-S/c-FLIPs is a major cellular inhibitor of TRAIL-
induced apoptosis. ß 2002 Federation of European Biochemi-
cal Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
TRAIL (tumor necrosis factor (TNF)-related apoptosis-in-
ducing ligand) is a recently identi¢ed member of the TNF
family that selectively induces apoptosis of cancer cells [1,2].
In mouse and primate models, TRAIL has been shown to
cause reduction in tumor growth rate and in some cases com-
plete elimination of tumors without detectable toxicity [3,4],
pointing to the possibility of developing TRAIL as a reagent
for cancer treatment.
TRAIL induces apoptosis through two death domain-con-
taining receptors, TRAIL-R1/DR4 and TRAIL-R2/DR5 [5,6].
Two additional receptors, TRAIL-R3/TRID/DcR1 and
TRAIL-R4 also bind to TRAIL [5,6]. TRAIL-R3 is a GPI-
linked receptor that does not have a cytoplasmic domain,
while TRAIL-R4 has a cytoplasmic domain containing one-
third of the consensus death domain motif. It has been sug-
gested that TRAIL-R3 and TRAIL-R4 function as ‘decoy’
receptors to inhibit TRAIL-induced apoptosis [7,8].
Although TRAIL can selectively induce apoptosis of certain
cancer cells, some cancer cells or subpopulations within cancer
cell lines are resistant to TRAIL. The molecular mechanisms
responsible for cells’ resistance to TRAIL are controversial.
Although it has been suggested that a cell’s resistance to
TRAIL-induced apoptosis might be caused by expression of
the ‘decoy’ receptors TRAIL-R3 and TRAIL-R4 [7,8], several
careful studies indicate that this is not the case, or at least is
not the only mechanism. In these studies, numerous cancer
cell lines were analyzed for their sensitivity to TRAIL in the
context of expression of di¡erent TRAIL receptors. These
studies indicated that there was no correlation between the
expression of potential ‘decoy’ receptors TRAIL-R3 and/or
TRAIL-R4 and a cell’s sensitivity to TRAIL [5,6,9,10].
Another potential mechanism responsible for a cell’s resis-
tance to TRAIL involves the activation of necrosis factor
(NF)-UB. Previously, several studies have established that
NF-UB activation can protect cells from TNF-induced apo-
ptosis, probably through its ability to induce the expression of
anti-apoptosis genes [11]. Recently, several studies indicated
that activation of NF-UB conferred resistance to TRAIL-in-
duced apoptosis [12,13]. However, these studies can not ex-
clude the possibility that NF-UB-independent proteins can
also inhibit TRAIL-induced apoptosis. In fact, other studies
showed that activation of NF-UB was not su⁄cient to block
TRAIL-induced apoptosis in certain cell types [14,15]. Thus,
both NF-UB-dependent and -independent proteins may be in-
volved in cells’ resistance to TRAIL-induced apoptosis.
To get a better understanding on the mechanisms of
TRAIL resistance, which is important to develop TRAIL
into a cancer drug, we have developed a retroviral cDNA
library-based functional cloning approach to unambiguously
identify genes that inhibit TRAIL-induced apoptosis. Our
¢ndings indicate that the short splice form of Casper/c-FLIP
(Casper-S/c-FLIPs) is a major cellular inhibitor of TRAIL-
induced apoptosis.
2. Materials and methods
2.1. Reagents and cell lines
Recombinant human soluble TRAIL (aa 95^291) was produced in
Escherichia coli and puri¢ed by our own laboratory. The retroviral
human leukocyte cDNA library (Clontech) and fetal liver cDNA li-
brary (Stratagene), and the packaging cell line 293-10A1 (Imgenex)
were purchased from the indicated manufacturers. HeLa cells were
provided by Dr. David Riches (National Jewish Medical and Re-
search Center). The mouse Casper(3/3) and wild-type embryonic
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¢broblasts (EFs) were previously described [16]. All cells described
above were cultured in Dulbecco’s modi¢ed Eagle’s medium contain-
ing 10% fetal calf serum.
2.2. Constructs
Casper/c-FLIP and Casper-S/c-FLIPs retroviral plasmids were con-
structed by insertion of their respective cDNAs into the retroviral
vector pFB-Neo (Stratagene).
2.2.1. MTT assays. Cells (V2U105) were cultured in 6-well
dishes and treated with various concentration of TRAIL for 6 h.
The apoptotic cells were then washed o¡ by PBS and the survival
cells were incubated in fresh medium with 0.5 mg/ml of MTT (Sigma)
for 6 h. The brown MTT-derivative crystals were dissolved in 1 ml of
70% isopropanol/0.02 N HCl, and the values at OD570 were read by a
spectrophotometer.
2.3. Isolation of TRAIL-sensitive HeLa clones
HeLa cells were seeded in 100 mm dishes at a density of V50 cells/
dish. Two weeks later, individual clones were pick up into 24-well
dishes. One week after seeding, cells from each well were split into
two wells. Cells in one well were treated with 100 ng/ml of TRAIL for
6 h. Only clones that all cells died were de¢ned as TRAIL-sensitive
clones and were used for further experiments.
2.4. Cell transfection and retroviral-mediated gene transfer
Cells were transfected by the standard calcium phosphate precipi-
tation method. Retroviral-mediated gene transfer was performed fol-
lowing the recommended procedures by the manufacturers (Imgenex
and Clontech).
To screen for genes that inhibit TRAIL-induced apoptosis, 293-
10A1 cells (V2U106/dish) were transfected with 15 Wg of human
leukocyte or fetal liver retroviral cDNA library plasmids by calcium
phosphate precipitation. 18 h later, the cells were washed with PBS
and cultured in 5 ml of fresh medium. 24 h later, the recombinant
retrovirus-containing medium was collected and centrifuged. The
supernatant, supplemented with 4 Wg/ml polybrene, was used to infect
TRAIL-sensitive HC1 (a HeLa subclone) cells (V2U106). Two days
after infection, the cells were treated with 200 ng/ml of TRAIL for 24
h, and then subjected to two more rounds of TRAIL treatment.
TRAIL-resistant clones were pick up and ampli¢ed. Genomic
DNAs of the resistant clones were extracted and the inserts of the
retroviral vectors integrated into the resistant clones were ampli¢ed by
PCR and sequenced. In these screening experiments, a total of
V2U107 cells were infected and 52 TRAIL-resistant clones were
obtained and sequenced.
2.5. Western blot
Western blot was performed with a rabbit polyclonal antibody rec-
ognizing both the long and short forms of Casper [17].
3. Results and discussion
To identify genes that inhibit TRAIL-induced apoptosis, we
have used HeLa cells as a model system. As shown in Fig. 1A,
TRAIL could induce apoptosis of HeLa cells in a dose-depen-
dent manner. At a concentration of 200 ng/ml, TRAIL could
kill approximately 95% of treated HeLa cells in 6 h. However,
V5% of treated HeLa cells were resistant (Fig. 1A), and these
cells remained resistant even when TRAIL concentration was
increased to 1000 ng/ml and the treatment time was extended
to 48 h (data not shown). To make sure the resistant pheno-
type is stable, we ampli¢ed the resistant cells and performed
¢ve more rounds of treatment with a high concentration of
TRAIL (1000 ng/ml). After these treatments, the cells were
completely resistant to TRAIL (Fig. 1B). We designated these
TRAIL-resistant cells as HeLa-TR.
There are at least two possible mechanisms that may ac-
count for HeLa-TR cells’ resistance to TRAIL. Firstly, one or
more intracellular signaling components of TRAIL-induced
apoptosis pathway are absent in the resistant cells; alterna-
tively, one or more inhibitory proteins are expressed in the
resistant cells but not or at low levels in the sensitive cells, and
these inhibitory proteins can inhibit TRAIL-induced apopto-
sis. To distinguish these two possibilities, we examined the
e¡ect of cycloheximide, a protein synthesis inhibitor, on
HeLa-TR cells’ response to TRAIL. We found that in the
presence of 2 Wg/ml of cycloheximide, TRAIL (200 ng/ml)
could induce apoptosis of almost 100% of treated HeLa-TR
cells in 6 h (Fig. 1B). In the same experiments, TRAIL or
cycloheximide alone had no apoptosis-inducing e¡ect on
HeLa-TR cells (Fig. 1B). Similar results were observed with
several other TRAIL-resistant cancer cell lines (data not
shown). These data suggest that the signaling components of
TRAIL-induced apoptosis pathway are intact in the resistant
cells and that one or more short-lived inhibitory proteins ex-
pressed in the resistant cells are responsible for resistance to
TRAIL-induced apoptosis.
To identify inhibitory genes of TRAIL-induced apoptosis in
resistant cells, we developed a retroviral cDNA library-based
functional cloning approach. The procedures are illustrated in
Fig. 1. A: TRAIL induces apoptosis of HeLa cells in a dose-dependent manner. HeLa cells were treated with the indicated amounts of TRAIL
for 6 h and the relative cell survival was measured by MTT assays. B: Conversion of TRAIL-resistant cells to sensitive cells by cycloheximide.
HeLa-TR cells were treated with TRAIL (200 ng/ml), cycloheximide (2 Wg/ml), or both together for 6 h and the relative cell survival was then
measured by MTT assays.
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Fig. 2. Brie£y, we ¢rstly isolated a HeLa subclone (HC1) that
is highly sensitive to TRAIL-induced apoptosis. At a concen-
tration of 200 ng/ml, TRAIL could kill V100% of treated
HC1 cells in 4 h (data not shown). To screen for TRAIL-
inhibitory genes, we transfected V5U107 of 293-10A1 pack-
aging cells with V150 Wg of retroviral human leukocyte and
fetal liver cDNA library plasmids by calcium phosphate pre-
cipitation. Since normal cells are resistant to TRAIL [5,6],
they should be ideal sources for potential TRAIL-inhibitory
genes. Therefore, we performed our functional cloning experi-
ments with the two commercially available retroviral cDNA
libraries.
Two days after transfection of the 293-10A1 packaging cells
with the retroviral cDNA library plasmids, recombinant ret-
rovirus-containing medium was collected and used to infect
V2U107 HC1 cells. The infected HC1 cells were subjected to
three rounds of treatment with TRAIL (200 ng/ml). The
TRAIL-resistant clones were ampli¢ed and the integrated in-
serts in the retroviral vector were ampli¢ed by PCR. Sequenc-
ing analysis indicates that 16 out of 52 TRAIL-resistant
clones encode Casper-S/c-FLIPs, which is corresponding to
aa 1^202 of the full-length Casper/c-FLIP [17^20]. In addition
to Casper-S/c-FLIPs, one of the TRAIL-resistant clones en-
codes a previously unidenti¢ed splice form of Casper/c-FLIP,
which is corresponding to aa 1^267 of the full-length Casper/
c-FLIP.
There are several possible reasons that the obtained clones
are resistant to TRAIL. Firstly, the protein encoded by the
cDNA insert in the retroviral vector can inhibit TRAIL-in-
duced apoptosis; secondly, the retroviral vector may insert
into and disrupt a gene required for TRAIL-induced apopto-
sis; thirdly, insertion of the retroviral vector may activate an
endogenous TRAIL-inhibitory gene. In the latter two cases,
the TRAIL-resistant phenotype of a clone is not caused by
expressed protein encoded by the cDNA insert of the inte-
grated retroviral vector.
To con¢rm that Casper-S/c-FLIPs can inhibit TRAIL-in-
duced apoptosis, we made a retroviral vector for Casper-S/c-
FLIPs. This vector was introduced into the TRAIL-sensitive
HeLa clone by retroviral-mediated gene transfer and the
transduced cells were selected by G418. The stable cell line
was treated with TRAIL or left untreated, and MTT assay
was performed to examine cell viability. These experiments
indicated that retroviral-mediated gene transfer of Casper-
S/c-FLIPs was su⁄cient to confer resistance to TRAIL-sensi-
tive cells (Fig. 3). As expected, crmA, a speci¢c caspase in-
hibitor, could also inhibit TRAIL-induced apoptosis (Fig. 3).
Similar experiments suggest that the other candidate genes
from the functional screening can not inhibit TRAIL-induced
apoptosis and therefore represent arti¢cial clones from the
screenings.
Casper/c-FLIP was identi¢ed as a FADD- and caspase-8-
related protein [17^20]. Casper/c-FLIP contains two death
e¡ector domains and a caspase-like domain. Casper/c-FLIP
is not a caspase because the conserved cysteine residue among
all caspases is not present in Casper/c-FLIP. There are several
alternative spliced transcripts detected in mammalian cells,
but only two forms of Casper/c-FLIP can be detected at the
protein level. These include the short form, Casper-S/c-FLIPs,
which contains aa 1^202, and the full-length long form, which
contains 480 aa. A viral protein, v-FLIP, is structurally re-
lated to the short form of Casper/c-FLIP and is a potent
inhibitor of apoptosis [19,20].
Previously, it has been shown that overexpression of Cas-
per-S/c-FLIPs can inhibit death receptor-mediated apoptosis.
Overexpression of the full-length Casper/c-FLIP protein, how-
ever, can either induce apoptosis or inhibit apoptosis, prob-
ably depending on protein expression levels and cell types [17^
20].
To further investigate Casper’s role in TRAIL-induced ap-
Fig. 2. Strategy for identi¢cation of TRAIL-inhibitory genes. See
text for details.
Fig. 3. Inhibition of TRAIL-induced apoptosis by ectopic expression
of Casper-S/c-FLIPs. The TRAIL-sensitive HeLa cells were stably
transduced with control, Casper-S/c-FLIPs, or crmA retroviral vec-
tors. The stably transduced cells were treated with TRAIL (200 ng/
ml) (black bars) or left untreated (white bars) for 6 h. Relative cell
survival was then measured by MTT assays. The protein levels of
Casper-S/c-FLIPs in the transduced cells were examined by Western
blot (lower panel).
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optosis, we examined the e¡ect of TRAIL on Casper/c-FLIP
gene knock-out EFs, referred hereafter as Casper(3/3) EFs.
We found that Casper(3/3) EFs were highly sensitive, while
their wild-type counterparts were completely resistant to
TRAIL-induced apoptosis (Fig. 4A). These data suggest
that Casper/c-FLIP is required and su⁄cient for EF cells’ re-
sistance to TRAIL-induced apoptosis. Since Casper(3/3) EFs
do not express either Casper-S/c-FLIPs or the full-length Cas-
per/c-FLIP [16], we determined their individual contribution
to EF cells’ resistance to TRAIL-induced apoptosis. To do
this, we re-introduced them into Casper(3/3) EFs by retro-
viral-mediated gene transfer and found that both of them
could signi¢cantly restore resistance to TRAIL-induced apo-
ptosis (Fig. 4B). However, Casper-S/c-FLIPs was more potent
than the full-length Casper/c-FLIP in inhibiting TRAIL-in-
duced apoptosis in Casper(3/3) EFs in these experiments.
This is consistent with the fact that we only isolated Casper-
S/c-FLIPs but not the full-length Casper/c-FLIP in our func-
tional cloning experiments. This is also consistent with some
recent studies suggesting that Casper-S/c-FLIPs is a more po-
tent inhibitor of apoptosis than the full-length Casper/c-FLIP
in various systems [21,22].
In conclusion, our ¢ndings suggest that Casper-S/c-FLIPs is
a major cyto-protective protein of TRAIL-induced apoptosis.
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Fig. 4. Casper-S/c-FLIPs is critically involved in cells’ resistance to TRAIL-induced apoptosis. A: Casper (3/3) but not wild-type EFs are sen-
sitive to TRAIL-induced apoptosis. Casper(3/3) and wild-type EFs were treated with TRAIL (200 ng/ml) or left untreated for 6 h. Relative
cell survival was then measured by MTT assays. B: Re-introduction of Casper-S/c-FLIPs into Casper(3/3) EFs restores resistance to TRAIL.
Casper-S/c-FLIPs and the full-length Casper/c-FLIP were re-introduced into Casper(3/3) EFs by retroviral-mediated gene transfer, then treated
with TRAIL (200 ng/ml) or left untreated for 6 h. Relative cell viability was then measured by MTT assays.
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